Ganciclovir Triphosphate - (N-9001)
9-(1
$0.00
Out of stock
default
N-9001
Description
Ganciclovir is a synthetic acyclic-DNA guanine derivative, where the C2’ carbon bond is absent. Ganciclovir Triphosphate (ganciclovir-TP, GCV-TP), the active metabolite of ganciclovir, is thought to disrupt viral DNA synthesis by competitive inhibition of viral DNA polymerases and by incorporation into viral DNA, to result in eventual termination of viral DNA elongation.
Ganciclovir was first published as 2'-Nor-2'-deoxyguanosine (2'NDG), with noted effectiveness in treating acute herpes simplex infections in mice. Recently it has been studied as an Epstein-Barr Virus treatment, as well as a prostate cancer, human cytomegalovirus (HCMV) retinitis and CMV antigeemia preemptive treatment. The triphosphorylated form (GCV-TP) is an important control in this research.
Product details
| Catalog No | N-9001 |
|---|---|
| Purity | ≥95% by AX-HPLC |
| Extinction Coefficient | 13,600 Lmol-1cm-1 at 252 nm |
| Molecular Formula | C9H16N5O13P3 (free acid) |
| Molecular Weight | 495.20 g/mole (free acid) |
| Salt Form | Li+ |
| Concentration | 100 mM |
| Buffer | H2O |
| Recommended Storage | -20°C or below |
| Other Name(s) | 9-(1 |
| Application | Aptamers |
| Backbone | 5'-Triphosphate |
| Base Analog(s) | Guanosine |
| Sugar Type(s) | RNA |
| Nucleotide Category | Non-nucleotide |
Technical documents
Safety Data Sheet Look-up
Products FAQS
Ask an Expert
Certificate of analysis
CoA search tool
Intellectual property
Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.
TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.
References
- Davis, David A.; Singer, Kathleen E.; Reynolds, Irene P.; Haque, Muzammel; Yarchoan, Robert . Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells.
- Zhu, Weimin; Burnette, Angela; Dorjsuren, Dorjbal; Roberts, Paula E.; Huleihel, Mahmoud; Shoemaker, Robert H.; Marquez, Victor E.; Agbaria, Riad; Sei, Shizuko . Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus.
- Dorjsuren, Dorjbal; Burnette, Angela; Gray, Glenn N.; Chen, Xulin; Zhu, Weimin; Roberts, Paula E.; Currens, Michael J.; Shoemaker, Robert H.; Ricciardi, Robert P.; Sei, Shizuko . Chemical library screen for novel inhibitors of Kaposi's sarcoma-associated herpesvirus processive DNA synthesis.
- Zhang, SM;Rehling, D;Jemth, AS;Throup, A;Land . NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir
